Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia

Prolonged isolated thrombocytopenia (PIT) is a complication following allogeneic hematopoietic cell transplantation that results in prolonged transfusion dependence. Recently, the efficacy of a thrombopoietin receptor agonist (eltrombopag) against PIT has been reported in adults; however, there are...

Full description

Bibliographic Details
Main Authors:	Megumi Matsumoto, Kazuki Terada, Taichiro Tsuchimochi, Satoko Takahashi, Yasushi Noguchi, Shunji Igarashi
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Hematology Reports
Subjects:	eltrombopag thrombopoietin receptor agonist prolonged isolated thrombocytopenia allogeneic stem cell transplantation
Online Access:	https://www.mdpi.com/2038-8330/14/3/33

Similar Items

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-12-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-11-01)

Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
by: Alhossain A. Khalafallah, et al.
Published: (2012-01-01)

Evaluation of safety, efficacy and pharmacokinetics of Eltrombopag in patients with chronic immune thrombocytopenia: Meta-analysis of randomized controlled trials Authors
by: Abdullah AL-Dhuraibi, et al.
Published: (2023-06-01)

Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology
by: Paola Giordano, et al.
Published: (2023-07-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01)

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
by: Olga S. Levchenkova, et al.
Published: (2023-03-01)

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01)

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently
by: Mohamed A. Yassin, et al.
Published: (2023-12-01)

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review
by: Elsayed A, et al.
Published: (2024-09-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01)

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01)

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA
by: Roberto Stasi, et al.
Published: (2009-11-01)

Renal transplant in a patient with idiopathic thrombocytopenic purpura refractory to steroid and intravenous immunoglobulin
by: Shubham Agarwal, et al.
Published: (2019-01-01)

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature
by: Roberto Castelli, et al.
Published: (2025-02-01)

Off Label Use of Eltrombopag and Recombinant Activated Factor VII in Wiskott-Aldrich Syndrome. A Case Report and Review of Literature
by: Alkistis Adramerina, et al.
Published: (2022-04-01)

Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View
by: Tomás José González-López, et al.
Published: (2023-04-01)

Impact of Eltrombopag Therapy in Different Lines of Treatment on Response in Patients with Immune Thrombocytopenia
by: Abdülkadir Karışmaz, et al.
Published: (2024-08-01)

A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation
by: Yu-Qian Sun, et al.
Published: (2019-11-01)

Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
by: María Henar García Lagunar, et al.
Published: (2015-02-01)

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
by: Ayça Koca Yozgat, et al.
Published: (2020-08-01)

Immune thrombocytopenia and cerebral thrombophlebitis in a patient on eltrombopag: A rare complication
by: Salma Fares, MD, et al.
Published: (2023-06-01)

Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin
by: Yahan Li, et al.
Published: (2024-04-01)

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
by: Demet Çekdemir, et al.
Published: (2019-11-01)

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
by: Pedro Marques Ramos, et al.
Published: (2023-08-01)

Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
by: Mehmet Baysal, et al.
Published: (2022-02-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
by: Abdulkadir Erçalışkan, et al.
Published: (2022-11-01)

Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
by: Mehmet Can Uğur, et al.
Published: (2021-08-01)

Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
by: M. V. Maevskaya, et al.
Published: (2024-08-01)

Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy
by: Giuseppe Palumbo, et al.
Published: (2023-12-01)

Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia
by: Feifei Yang, et al.
Published: (2023-01-01)

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
by: Zeynep Tuğba Güven, et al.
Published: (2022-05-01)

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure
by: Davide Scalabrini, et al.
Published: (2023-08-01)

Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01)

Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia
by: Ondine Walter, et al.
Published: (2022-11-01)

Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single‐center observational study in China
by: Shuyue Dong, et al.
Published: (2024-03-01)

Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension
by: Hanny Al‐Samkari, et al.
Published: (2022-02-01)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018-11-01)